Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy
Status:
Terminated
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
A pilot trial of combination of bortezomib, bevacizumab and carboplatin as first line therapy
in patients with metastatic Non-Small Cell Lung Cancer (NSCLC). Phase I and II study of this
combination in first line setting will be conducted in order to properly estimate the
efficacy and safety of this regimen. This will form the basis for future studies comparing
this combination to what is now considered standard regimen for first line therapy in
patients with NSCLC, carboplatin, paclitaxel and bevacizumab.